Chongqing Pharscin Pharmaceutical Co., Ltd.

Shenzhen Stock Exchange 002907.SZ

Chongqing Pharscin Pharmaceutical Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2023: 2.02%

Chongqing Pharscin Pharmaceutical Co., Ltd. Return on Equity (ROE) is 2.02% for the year ending December 31, 2023, a -66.92% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.
  • Chongqing Pharscin Pharmaceutical Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2022 was 6.11%, a -15.72% change year over year.
  • Chongqing Pharscin Pharmaceutical Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2021 was 7.25%, a -28.11% change year over year.
  • Chongqing Pharscin Pharmaceutical Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2020 was 10.09%, a -36.38% change year over year.
  • Chongqing Pharscin Pharmaceutical Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2019 was 15.85%, a -4.35% change year over year.
Key data
Date Return on Equity (ROE) Return on Capital Employed (ROCE) Interest Coverage Ratio Debt to Equity Ratio
Market news
Loading...
SV Wall Street
Shenzhen Stock Exchange: 002907.SZ

Chongqing Pharscin Pharmaceutical Co., Ltd.

CEO Ms. Xiaoying Liu
IPO Date Oct. 20, 2017
Location China
Headquarters No. 89, Middle Sec of Huangshan Ave
Employees 1,411
Sector Healthcare
Industries
Description

Chongqing Pharscin Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of drugs in China. The company offers tablets, powders, granules, hard capsules, soft capsules, powder injections, freeze-dried powder injections, small volume injections, and API synthesis. It provides its products in the areas of CNS, digestion, otolaryngology, oncology, cardiovascular, and cerebrovascular related diseases. Chongqing Pharscin Pharmaceutical Co., Ltd. was founded in 1996 and is headquartered in Chongqing, China.

StockViz Staff

February 3, 2025

Any question? Send us an email